.webp)
67/100BRoyalty Pharma company profile
- CEO
- Pablo Legorreta
- Employees
- 100
- Headquarters
- 110 East 59th Street, New York, NY 10022, US
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- IPO date
- 16 Jun 2020
- Stock exchange
- NASDAQ
- ISIN
- GB00BMVP7Y09
Website:royaltypharma.com
About the company
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Employees
Royalty Pharma had about 100 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 1.0% more than a year before.
Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.
Who owns Royalty Pharma
Institutions such as funds, banks and insurers held 83.2% of Royalty Pharma's shares on 30 June 2026, 660 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Common questions about Royalty Pharma
Source: Financial Modeling Prep